Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Completed · Phase 2
Conditions studied: Acoustic Schwannoma, Adult Anaplastic Meningioma, Adult Ependymoma, Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Meningeal Hemangiopericytoma, Adult Papillary Meningioma, Neurofibromatosis Type 1, Neurofibromatosis Type 2, Recurrent Adult Brain Tumor
In brief
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well bevacizumab works in treating patients with recurrent or progression meningiomas.
Key facts
- Study ID
- NCT01125046
- Run by
- Northwestern University
- People needed
- 50
- Starts
- 2010-06-17
- Expected to finish
- 2018-12-31
- Last updated by the study team
- 2021-01-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Northwestern University — Chicago, Illinois, United States
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
- Columbia University Medical Center — New York, New York, United States
- University of Virginia — Charlottesville, Virginia, United States
- University of Washington — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.